Text Size: a  |   a 

Momenta Announces Publication of Two Glatopa Manuscripts

October 26, 2015

Momenta Pharmaceuticals announced today the recent publication of two peer-reviewed manuscripts that summarize the equivalence between Glatopa and daily Copaxone. Glatopa is the first FDA-approved generic version of daily Copaxone for patients with relapsing forms of multiple sclerosis.  This US-produced drug has been determined by the FDA to be therapeutically equivalent to daily Copaxone 20mg.

Copaxone is generally the first line of therapy that newly-diagnosed patients receive, and Glatopa contains the same active ingredients, route, strength and dosage form. This means that a patient who is substituting Glatopa for Copaxone can expect the same effect and efficiency from the drug.

  • "Equivalent Gene Expression Profiles between Glatopa™ and COPAXONE®," in PLOS ONE, can be found at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140299